Tri Locum Partners’s Cytokinetics CYTK Stock Holding History

Tri Locum Partners’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-33,379	Closed	-$1.52M	–	42
2021 Q4	$1.52M	Buy	+33,379	New	+$1.29M	0.6%	28

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Tri Locum Partners's CYTK Position: Q1 2022 in Review

Tri Locum Partners sold out of Cytokinetics (CYTK) in Q1 2022, closing a stake of 33,379 shares — an estimated $1.52M sold.

Tri Locum Partners first reported a position in CYTK in Q4 2021 and held it in 1 quarter. The position peaked at $1.52M in Q4 2021. 240 funds tracked by Wall St. Rank hold CYTK as of Q1 2022.

Tri Locum Partners reported no remaining Cytokinetics position as of Q1 2022 after selling out during the quarter.
Tri Locum Partners sold 33,379 Cytokinetics shares in Q1 2022, an estimated $1.52M.
Tri Locum Partners first reported a position in Cytokinetics in Q4 2021 and held it in 1 quarter.
Tri Locum Partners's Cytokinetics position peaked at $1.52M in Q4 2021.
240 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2022.

Based on Tri Locum Partners's 13F filing for Q1 2022, filed 16 May 2022.